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Abstract Long Interspersed Elements (L1 elements) are
biologically active retrotransposons that are capable of
autonomous replication using their own reverse transcrip-
tase (RT) enzyme. Expression of the normally repressed
RT has been implicated in cancer cell growth. However, at
present, little is known about the expression of L1-encoded
RT activity or the molecular changes that are associated
with RT activity in the development of breast cancer. Here,
we report that RT activity is widespread in breast cancer
cells. The expression of RT protein decreased markedly in
breast cancer cells after treatment with the antiretroviral
drug, efavirenz. While the majority of cells showed a sig-
nificant reduction in proliferation, inhibition of RT was
also accompanied by cell-specific differences in morphol-
ogy. MCF7 cells displayed elongated microtubule exten-
sions that adhered tightly to their substrate, while a large
fraction of the T47D cells that we studied formed long
filopodia projections. These morphological changes were
reversible upon cessation of RT inhibition, confirming their
dependence on RT activity. We also carried out gene
expression profiling with microarrays and determined the
genes that were differentially expressed during the process
of cellular differentiation. Genes involved in proliferation,
cell migration, and invasive activity were repressed in RT-
inhibited cells. Concomitantly, genes involved in cell
projection, formation of vacuolar membranes, and cell-to-
cell junctions were significantly upregulated in RT-inhib-
ited cells. qRT-PCR examination of the mRNA expression
of these genes in additional cell lines yielded close corre-
lation between their differential expression and the degree
of cellular differentiation. Our study demonstrates that the
inhibition of L1-encoded RT can reduce the rate of pro-
liferation and promote differentiation of breast cancer cells.
Together, these results provide a direct functional link
between the expression of L1 retrotransposons and the
development of breast cancer.
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Introduction
Retrotransposons are mobile genetic elements that replicate
through an RNA intermediate, which is subsequently
copied into genomic DNA by a reverse transcriptase
enzyme. At least 45 % of the human genome is derived
from repetitive elements formed from retrotransposons.
Depending upon whether they contain long terminal
repeats (LTRs), retrotransposons are classified into LTR
elements (human endogenous retroviruses, HERVs), non-
LTR elements (long interspersed elements, LINE-1 or L1
elements), and short interspersed elements (SVA and Alu
R. Patnala  S.-H. Lee  J. E. Dahlstrom  S. Ohms  L. Chen 
D. Rangasamy (&)
John Curtin School of Medical Research, The Australian
National University, Canberra, ACT 2601, Australia
e-mail: danny.rangasamy@anu.edu.au
R. Patnala  S. T. Dheen
Department of Anatomy, Yong Loo Lin School of Medicine,
National University of Singapore, Singapore 117597, Singapore
S.-H. Lee
Department of Molecular and Cellular Oncology, The University
of Texas MD Anderson Cancer Center, Houston, TX 77030,
USA
J. E. Dahlstrom
Department of Anatomical Pathology, The Canberra Hospital,
Garran, ACT 2605, Australia
123
Breast Cancer Res Treat (2014) 143:239–253
DOI 10.1007/s10549-013-2812-7
elements). L1 elements are the most prolific type of ret-
rotransposon and are capable of mediating insertional
mutations, and genome reorganization through their
reverse transcriptase enzyme leading to a number of human
diseases (reviewed in [1, 2]). There are approximately
7,000 copies of full-length L1 elements in the human
genome, at least 100 of which are classified as highly
active or retrotransposition-competent [3, 4]. An active L1
element is composed of a 50-untranslated region, which
contains an internal promoter, two open reading frames
(ORF1 and ORF2), and a 30 poly-A tail. ORF1 encodes an
RNA-binding protein, whereas ORF2 encodes the reverse
transcriptase (RT) and endonuclease enzymes, which are
required for the reverse transcription of an L1 RNA
intermediate into DNA and the insertion of DNA copies
into new genomic locations using a ‘copy-and-paste’
mechanism [2]. In addition, L1-encoded RT also facilitates
the retrotransposition of Alu elements, certain mRNAs and
noncoding RNAs to new sites in the host genome [5, 6],
thereby reshaping the genome in additional ways. Similar
to the L1 element, the HERV element is an autonomous
LTR element that can integrate a reverse-transcribed DNA
copy of its sequence into the genome using its endogenous
RT activity [7]. Since all classes of retrotransposons,
except for Alu and SVA elements, contain an RT-encoding
gene, the activity of RT has been implicated in a range of
retrotransposon-mediated human diseases [8, 9]. Further-
more, the presence of RT itself, has been associated with
several cellular and physiological disorders [10].
The majority of human cancer cells, cancer-derived cell
lines and a variety of transformed cells have a high level of
L1 expression, but L1 elements are rarely expressed in
noncancerous cells or morphologically differentiated
somatic tissues [11–13]. It has also been shown that the
breast carcinoma-derived T47D cell line releases retrovi-
ral-like particles that possess a high level of RT activity
[14]. The level of RT is also particularly high in patients
with lymphoma and breast cancer, but drops dramatically
after cancer treatment [15, 16], suggesting a potential link
between RT activity and the proliferative potential of
cancer cells. Several studies have shown that antiretroviral
non-nucleoside reverse transcriptase inhibitors (NNRTIs)
such as efavirenz and nevirapine bind to a hydrophobic
region of the RT enzyme, inducing a conformational
change in the enzyme and consequently inhibiting RT
activity [17]. Efavirenz is a first-line antiretroviral drug,
and is widely used to treat HIV-1 infections. Recently,
Efavirenz has been reported to suppress the activity of the
L1-encoded RT enzyme, similar to the effect of small
interference RNA against L1 elements, and to promote
morphological differentiation in melanoma A-375 cells
[18, 19]. Consistently, other NNRTI drugs have been found
to inhibit L1 retrotransposition activity in a number of
human cells [20–22]. More recently, another class of RT
inhibitors, the nucleoside reverse transcriptase inhibitors
(NRTIs) have also been shown to suppress L1 activity and
to induce anticancer activity in prostate cancer cell lines
[23], suggesting that inhibition of the L1-encoded RT
might be a potential target for diagnostic and therapeutic
intervention. Despite these findings, many questions
remain unclear about the molecular changes, and the extent
of changes in gene expression that result from RT inhibi-
tion. Moreover, little is known about how inhibition of RT
can lead to morphological changes in cancer cells.
Breast cancer is the most common malignant diseases
with an increasing worldwide incidence and is a leading
cause of death in women. There is an urgent need to
diagnose and treat breast cancer in its early stages. We
recently discovered that L1 elements are differentially
expressed between normal and breast tumor tissues. L1 is
barely expressed, if at all, in normal healthy cells, while in
contrast, it is overexpressed in almost all breast cancer cells
and clinical samples [24, 25]. However, little is known
about the role of L1 elements or L1-encoded RT activity in
the process of breast cancer development. Given that
NNRTIs can inhibit RT activity, we investigated the anti-
cancer effects of efavirenz on various breast cancer cell
lines. Here, we report that inhibition of RT promotes
growth arrest, differentiation, and morphological changes
in cancer cells. We also demonstrate that efavirenz acti-
vates differentiation-specific gene expression signatures
and reprograms the activation of many genes that can
restore control of the growth and differentiation processes
of breast cancer cells.
Materials and methods
Cell cultures and drug treatments
Normal human breast epithelial cells (HMECs) and mam-
mary epithelial growth medium (MEGM Bullet Kit) were
obtained from Lonza (Walkersville, MD). The HMEC
(Lonza-CC-2551) and non-tumorigenic MCF10A cells
(ATCC-CRL-10371) were cultured in the MEGM Bullet
Kit (Clonetics) supplemented with 10 lg/ml of insulin.
MCF7, T47D, SKBR3, Hs578T, BT20, HBL100, and
MDA-MB-231 cell lines were obtained from ATCC and
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
with 2 mM L-glutamine and 10 % FCS at 37o C in 5 %
CO2. MDA-MB-361 cells were cultured in Leibovitz’s
L-15 Media (Invitrogen) with 20 % FBS. Efavirenz was
obtained from the NIH AIDS Research and Reference
Reagent Program. Efavirenz was dissolved in dimethyl
sulfoxide (DMSO) at a final concentration of 0.2 % and
used at concentrations of 15 and 45 lM as described
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previously [18]. The same volume of DMSO was added to
controls. Cells were treated with or without drug 24 h after
seeding into 6-well plates at a density of 2 9 104 cells/
well. Medium was replaced with fresh efavirenz or DMSO
every 24 h. Cells were harvested after 72 h of treatment.
To assess the effect of drug withdrawal, cells were treated
with drug for 72 h, then washed twice with PBS and cul-
tured in fresh medium for 48 h without drug or DMSO.
Western blot analysis
Cell lysates were prepared using MPER reagent (Pierce).
Protein samples were separated on a 4–12 % Bis–Tris
polyacrylamide gel (Invitrogen) and transferred onto Nylon
membranes (GE Healthcare). Western blot analysis was
performed with anti-L1 ORF2p antibodies at 1:3000 dilu-
tion [25], followed by addition of HRP-conjugated sec-
ondary antibodies (Dako Cytomation). The resulting
signals were visualized using the ECL chemiluminescence
system (Pierce) and quantified by densitometry using NIH
ImageJ software. To confirm protein normalization, the
membranes were stripped and reprobed with a-tubulin
antibodies (Sigma).
Reverse transcriptase assay
Whole-cell lysates were prepared as described previously
[23]. RT assays were carried out in 20-ll reactions con-
taining 10 ng of MS2 phage RNA (Roche) and RT-PCR
reaction buffer (Invitrogen), 0.5 mM of dNTP mix, 2U of
RNAseOUT, 50 pmol of MS2 reverse primer, and 20 lg of
whole-cell lysates. The reaction mixture was incubated at
55 C for 60 min, followed by addition of 2U of RNaseH
(Invitrogen) and incubated further at 37 C for 20 min.
Control reactions were set up by either omitting cell lysates
or adding 1 ll of commercially available RT enzyme
(Invitrogen). About 2 ll of the resulting reaction was
subsequently amplified using the MS2 primers: forward 50-
CCTGCTCAACTTCCTGTCGAG-30, reverse 50-CATAG
GTCAAACCTCCTAGGAAT-30. PCR was carried out at
standard amplification parameters (95 C for 10 min, fol-
lowed by 30 cycles of 95 C for 15 s, 55 C for 30 s and
72 C for 45 s and final extension at 72 C for 5 min). The
PCR products were analyzed by electrophoresis using a
2 % agarose gel.
Quantitative RT-PCR analysis
Total RNA was isolated from cells using an RNeasy Kit
(Qiagen) and digested with TurboDNase-I (Ambion).
About 2 lg of purified RNA was used for cDNA synthesis
with 0.1 lg random decamer primers using a RETRO-
Script RT kit (Ambion). The resulting cDNAs were used as
templates for real-time qRT-PCR with specific primers for
L1 ORF1 and ORF2 and a selection of genes found to be
differentially expressed genes including CDC42, EXOC4,
PARD3, PTPA4, and HPRT1: L1 ORF1 forward 50-GGTT
ACCCTCAAAGGAAGCC-30, reverse 50-GCCTGGTGAC
AAAATCTC-30; L1 ORF2 forward 50-AAATGGTGCTGG
GAAAACTG-30, reverse 50-GCCATTGCTTTTGGTGTTTT
-30; CDC42 forward 50-CATCTCTCCAGAGCCCTTTC-30,
reverse 50-TGCAGGGCATTTGTCATTAT-30; EXOC4 for-
ward 50-CTGGACTTTGCAAGGCAGTA-30, reverse, 50-CT
CCAGCTCCGTGTACTTCA-30; PARD3 forward 50-TTGA
TGAGCAGGATCCACAT-30, reverse, 50-AGGCTGAAAG
GCTGAGACAT-30; PTPA4 forward 50-ATGAGAAACGTG
GTTTGCAG-30, reverse, 50-GATGCAGGAAGCCTGAAGT
T-30; HPRT1 forward 50-CCTGGCGTCGTGATTAGTGAT-30,
reverse 50-AGACGTTCAGTCCTGTCCATA-30. As a negative
control, we synthesized cDNA in the absence of reverse trans-
criptase and primers. Real-time qRT-PCR was carried out with
SYBR Green PCR master mix and a 7900HT thermal cycler
(Applied Biosystem) with typical amplification parameters
(50 C for 2 min and 95 C for 10 min, followed by 40 cycles of
95 C for 15 s and 60 C for 1 min). Fold changes were deter-
mined by comparing the DCT value of each gene normalized to
the reference control HPRT1 for each reaction. Data generated
were the average of three independent experiments, with each
experiment performed in triplicate and analyzed using the Rela-
tive Expression Software Tool (http://REST.gene-quantification.
info).
Cell proliferation and cell cycle analysis
Cells were seeded in 96-well plates at a density of
1 9 103 cells/well in 100 ll of culture medium with or
without drug for 72 h. Proliferation of cells in response to
drug were determined with an ELISA reader after staining
with XTT (2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide) at various time points, as
described by the manufacturer (Applichem). Assessment of
apoptosis was carried out using combined staining with PI
and FITC-labelled Annexin V (BD Biosciences), following
the manufacturer’s instructions. The cell-cycle phase dis-
tribution was determined by flow cytometry. In brief, cells
were stained with 7AAD (7-amino-actinomycin D), and
incubated with Anti-Human Ki-67 Alexa Fluor647 anti-
body (eBiosciences) at 1:150 dilutions for 30 min at 4 C.
Cells were then analyzed using a LSRFortessa cell analyzer
(BD Biosciences), and data analyzed using FlowJo version
7.6.4 software.
Immunofluorescence analysis
Cells were grown on glass coverslips in 12-well plates at a
density of 1 9 103 cells per well. Cells were fixed in 4 %
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paraformaldehyde for 10 min and permeabilized in 0.25 %
Triton X-100 for 15 min. Mouse monoclonal anti-tubulin
antibody (Sigma) was visualized by staining with FITC-
conjugated secondary antibody (Jackson ImmunoRe-
search). Nuclei were stained with 0.1 lg/ml DAPI. Images
were overlaid in Adope Photoshop.
Scanning electron microscopy
Cells were fixed in 2 % glutaraldehyde in 0.1 M sodium
cacodylate buffer, pH 7.4 at 4 C overnight, followed by
secondary fixation with 1 % osmium teroxide for 90 min
and then dehydrated with increasing concentrations of
acetone. Sample’s critical-point drying was performed with
liquid CO2 using Balzers CPD-020, Liechtenstein, fol-
lowed by gold coating with a Polaron gold coater. Images
were taken with a Hitachi S-4300SE/N electron micro-
scope at 3 kV, aperture no. 3 and 9.7 mm.
Microarray analysis
Total RNA was isolated from cells using an RNeasy Kit
(Qiagen) and the RNA integrity evaluated with an Agilent
2100 Bioanalyzer. Approximately 20-lg RNA was labeled
with Cy3-conjugated dCTP (Amersham) using the Prime-
Script (Takara) reverse transcriptase. Labeled cDNA was
hybridized for 16 h at 42 C to Roche NimbleGen Human
Whole Genome 12-plex arrays according to the manufac-
turer’s protocol. The arrays were analyzed with an Axon
GenePix 4000B scanner and associated software (Molec-
ular Devices). Gene expression levels were calculated with
NimbleScan Version 2.4 (Roche NimbleGen, Inc., WI).
Relative signal intensities for each gene were generated
using the Robust Multi-Array Average algorithm with
quantile normalization and summarized by the median
polish method with NimbleScan Version 2.4 (Roche
NimbleGen). The log2 gene expression values were then
analyzed for fold changes in GeneSpring GX 11 (Agilent
Technologies, CA). The criteria for differential gene
expression were that gene expression levels be at least
2-fold upregulated or 0.5-fold downregulated compared to
control values, combined with a p value B 0.5 after cor-
rection for multiple testing with the Benjamini–Hochberg
algorithm.
Functional clustering analysis
The DAVID functional annotation tool, from NIH (http://
david.abcc.ncifcrf.gov/tools), was used for gene ontology
(GO) enrichment analysis, using the DAVID default
human population background. Three lists of genes
(upregulated or downregulated 2-fold or greater) were
uploaded to the DAVID website, which analyses gene lists
and clusters genes into groups according to enrichment of
annotations compared to a background gene list. The fre-
quency of each GO term keyword in a gene list is com-
pared to that for the entire human genome (termed the
‘‘background’’), providing a measure of enrichment of a
particular annotation in a gene list compared to what would
be expected from random chance. An enrichment p value
based on a hypergeometric test is calculated together with a
p value corrected for multiple testing. The enrichment
p values for a cluster of similar annotation terms can be
combined and an average value calculated using a geo-
metric mean to give a single enrichment score for a cluster.
An enrichment score C 1.3 is regarded as statistically
significant by DAVID.
Statistical analysis
The data obtained from all experiments were expressed as
the mean ± SD of three independent experiments with
each experiment performed in triplicate. A two-tailed
unpaired student’s t test was used to estimate statistical
significance using Prism software (GraphPad Software, San
Diego, CA). P (probability) \ 0.05 was accepted as sta-
tistically significant.
Results
RT activity in breast cancer cells
In a recent study we reported that L1-encoded ORF2p,
which contains the reverse transcriptase (RT) enzyme, is
significantly overexpressed in breast tumors of various
stages and grades [25], but the functional significance of
this increase in expression was unclear. To gain insight into
the mechanisms by which L1-encoded RT contributes to
breast cancer, we first evaluated endogenous RT activity in
primary mammary epithelial cells (HMEC or its immor-
talized cell line counterpart, MCF10A) and a panel of
breast cancer cell lines (MCF7, T47D, SKBR3, Hs578T,
BT20, MCF-7, MDA-MB-361, MDA-MB-436, and MDA-
MB-231). Extracts isolated from these cells were used as
sources of RT to reverse transcribe a synthetic MS2 phage
RNA. The NTera.2D1 human embryonic carcinoma cell
line, which expresses high levels of L1 protein [13], were
used as a positive control. As shown in Fig. 1a, RT activity
was found in all breast cancer cell lysates tested, indicating
that the synthetic MS2 RNA had been successfully reverse-
transcribed into a cDNA product at the expected band size
of 110 bp. As expected, none of the normal breast
MCF10A or HMEC cell lines showed RT activity, sug-
gesting that RT proteins are abundantly present in breast
cancer cells but not in non-tumorigenic cell lines.
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To further assess the expression profile of RT across this
panel, cell lysates were subjected to western blot analysis
for L1 RT expression using anti-L1 ORF2p antibodies [25].
Despite the assay not being quantitative, this analysis
revealed that all breast cancer cells express L1 ORF2p at
the expected size of *150 kDa (Fig. 1b). The MCF10A
normal breast cell line showed no expression except for
occasional background staining. Furthermore, the relative
expression levels of L1 ORF2 mRNA, which is an essential
prerequisite of RT, were notably higher in some of the
noninvasive and marginally invasive cell lines (T47D,
SKBR3, MCF7, and Hs578T) compared to the highly
invasive breast cancer cell lines (MDA-MB-231, MDA-
MB-436) as measured by qRT-PCR assays (Fig. 1c). This
suggests that RT might become activated in the early stages
of malignant transformation. The observation of early
activation of L1-encoded RT is in agreement with DNA
methylation studies in which the early onset of L1
demethylation has been reported to activate L1 expression
during cancer progression [26]. Overall, these results sug-
gest that L1-encoded RT activity is widespread in breast
cancer cells, and that it could, in principle, serve as a target
to inhibit its activity and to understand the function of RT
activity in cancer cells.
RT inhibition promotes cellular differentiation
RT inhibitors such as nevirapine and efavirenz are com-
monly used in antiretroviral therapy for patients infected
with HIV-1. Their key role is to inhibit the catalytic
activity of the RT p66 subunit, thereby blocking viral DNA
synthesis [17, 27]. In humans, the most abundant source of
RT activity are L1 retrotransposons, which represent
approximately 21 % of the genome, and thus L1-encoded
RT is assumed to be one of the targets of RT inhibitors.
Recent studies show that efavirenz has a higher affinity to
L1-encoded RT than nevirapine [21, 22] and is a more
effective inhibitor of RT activity. To analyse the effect of
inhibiting L1-encoded RT, we used efavirenz at concen-
trations of 15 and 45 lM as described previously [18]. The
noninvasive breast cancer T47D cells, which possess a high
level of RT activity [14], were treated with efavirenz for
72 h or mock-treated DMSO without drug, followed by an
assessment of the effect of drug treatment on L1 protein
expression. As shown in Fig. 2a, an approximately 70 %
decrease in the level of L1-encoded RT protein was
observed in T47D cells after efavirenz treatment
(71 ± 4 % for 15 lM and 77 ± 9 % for 45 lM of efavi-
renz compared with mock-treated cells as measured by
densitometry using NIH ImageJ software). To further
confirm the decrease in expression of L1 RT protein, we
measured the relative expression of L1 mRNA using qRT-
PCR analysis (Fig. 2b). In this assay MCF10A cells, which
do not express L1 mRNA, served as controls. As expected,
a two-fold decrease in the levels of ORF2 mRNA
(p \ 0.001, unpaired t test) was observed in both 15 and
45 lM efavirenz-treated cells compared with mock-treated
cells. Interestingly, we did not observe significant changes
in the expression of L1 ORF1 mRNA (p [ 0.05), although
the relative levels of ORF1 mRNA expression were lower
Fig. 1 L1-encoded RT activity in breast cancer cells. a Endogenous
RT activity was detected after incubation of synthetic MS2 phage
RNA with cell extracts from a panel of breast cancer cells. Control
reactions were set up by omitting cell extract (negative control) or
adding cell extracts from NTera.2D1 human embryonic carcinoma
cells (positive control). The PCR product of 110 bp (corresponding to
the reverse-transcribed MS2 cDNA) is shown. Marker, 1 kb-plus
DNA marker. b The L1-encoded ORF2p, which contains the RT
enzyme, was detected by western blotting of whole-cell lysates from
normal and a panel of breast cancer cells. NTera.2D1 were used as
positive controls. For protein normalization, a-tubulin was used as a
loading control. c The L1 ORF2 mRNAs derived from L1 expression
were quantified by qRT-PCR with primer specific for the ORF2
sequence. The data are shown as fold change in each breast cancer
panel cells compared to normal MCF10A after normalization to the
HPRT1 housekeeping gene. Each point represents the average of
three independent experiments, with each experiment performed in
triplicate. Error bars indicate SD (n = 3)
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in cells treated with drug compared with mock-treated
cells.
Normal epithelial cells synthesize adhesion proteins and
assemble and adhere to extracellular basement membranes
such as laminin and fibronectin and a loss of the ability to
interact with the basement membrane is one of the features
of the neoplastic proliferation of epithelial-derived cancer
cells [28, 29]. In fact, the phenotypic changes associated
with extracellular matrix interactions are often used as
criteria to establish the degree of differentiation in cancer
studies and pathological diagnosis [30]. Having confirmed
that efavirenz can effectively inhibit L1 RT expression, we
next investigated the phenotypic changes that occur during
drug treatment. MCF10A normal breast cells and T47D
and MDA-MB-231 breast cancer cells were cultured with
15 lM efavirenz for 72 h. The noninvasive T47D cancer
cells showed significant cellular differentiation following
efavirenz treatment. A majority of the drug-treated cells
exhibited monolayer growth, with distinct cell borders and
shapes. In contrast, control cells grew in multilayer clumps
with indistinct cell borders (Fig. 2c). Notably, the
MCF10A normal breast cell line did not show any changes
in cellular differentiation either with, or without drug
treatment. This was mainly due to the lack of L1
Fig. 2 RT inhibition promotes differentiation in breast cancer cell
lines. a Western blots of L1-encoded RT protein in normal
(MCF10A) and breast cancer (T47D) cells after treatment with 15
and 45 lM efavirenz for 72 h. The analyses of the parental cells
(control) and cells treated with DMSO (mock) were performed in
parallel. a-tubulin was used as an internal control. b Quantitative real-
time RT-PCR analysis of endogenous L1 mRNAs in T47D cells that
were treated with 15 and 45 lM efavirenz or DMSO for 72 h. The
MCF10A cell line was used as a negative control. The data are shown
as the relative fold changes of ORF1 and ORF2 mRNAs with respect
to the control HPRT1. The error bars indicate SD (n = 3). Unpaired
t test, * p [ 0.05 and ** p \ 0.001. c Morphological differentiation
of normal MCF10A and breast cancer T47D and MDA-MB-231 cells
after treatment with 15 lM efavirenz or DMSO (control) for 72 h.
Representative panels from phase-contrast microscopy are shown.
Bar 50 lM. d Phase-contrast microscopy of weakly-and moderately-
invasive breast cancer cells. Cells exposed to DMSO (control) or
efavirenz were examined in vivo after 72 h of culture to assess
morphological changes. The arrows indicate the appearance of
filopodial projections on the cell edges. e Quantitative morphological
changes. The percentages of morphological changes in drug-treated
cells were calculated by comparison to mock DMSO-treated cells or
parental cells in 100 cells from ten randomly selected fields. Each
point represents an average from two independent experiments.
P values were calculated by unpaired t test in comparisons to mock-
treated and parental cells. Error bars indicate SD
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expression in MCF10A cell line. Interestingly, the highly
invasive metastatic MDA-MB-231 cells responded poorly
to drug treatment, even after 50 lM efavirenz (a three-fold
higher concentration) and 120 h of exposure (data not
shown). These observations suggest that efavirenz selec-
tively controls the differentiation of some, but not all,
breast cancer cells.
To further confirm if the response to drug treatment
varied between the different cell types in the panel, we
assessed the effect of efavirenz on the differentiation of
several other noninvasive and marginally invasive breast
cancer cells (SKBR3, MCF7, HBL100, and Hs578T). We
found that cellular differentiation, as denoted by cell shape,
a decreased tendency to form aggregates, and increased
cell adhesion, became apparent after exposure to drug
compared to control cells (Fig. 2d). This development of a
differentiated morphology is in agreement with previous
study where similar changes in morphology were noticed
in nevirapine-treated breast carcinoma cell lines [31].
Using phase-contrast microscopy (n = 100 cells from ten
randomly selected fields), we quantified the percentage of
differentiation based on morphological changes such as
changes in cell shapes and cell adhesion, or the presence of
distinct cell borders. In parallel we also evaluated whether
these morphological changes had an effect on the structure
of the cytoskeleton using immunofluorescence assays as
described in previous reports [18, 31]. These included
structural changes in the cytoskeleton, notably the forma-
tion of elongated microtubules and monolayer cell growth.
T47D cells showed the greatest response, with a 4.5-fold
increase in the rate of cell differentiation (Fig. 2e). A
similar effect was also seen in MCF7 and Hs578T-treated
cells, although it was quantitatively less pronounced,
indicating that RT inhibition may play a key role in the
differentiation of some of the breast cancer cell lines.
Effects of RT inhibition on filopodia formation
Cellular differentiation is often characterized by the for-
mation of elongated microtubules, with the cells resuming
contact inhibition and developing into monolayer cultures
[32]. On the other hand, cancer cells lose contact inhibition
and proliferate as multilayers with indistinct cell borders.
Filopodia and microvilli are believed to play important
roles in cell-to-cell contact between layers and in aligning
cells when they adhere to extracellular matrix (reviewed in
[33, 34]). The formation of filopodia occurs when cells
move along certain cell differentiation-related pathways. It
has been shown that filopodia formations occurs in cells
following induction of CDC42 [35] and that filopodia are
the location of many functionally important membrane
proteins, which are involved in signal transduction path-
ways, glucose transport and energy metabolism required
for morphological differentiation [36, 37]. Interestingly,
the microtubule cytoskeletons are also required for spatial
regulation of filopodia projections [38]. Although the exact
functions of filopodia remain unclear, the increased num-
bers of filopodia structures have been shown to affect
cellular morphology by changing the attachment of cells to
adjacent surfaces [33].
Since efavirenz induces cellular differentiation, we
wondered whether the process of differentiation was due to
the formation of filopodia projections. Our observation of
cells under phase-contrast microscopy and immunofluo-
rescence assays (using randomly selected fields) revealed
clear signs of differentiation in drug-treated cells, with the
appearance of cell surface projections and elongated
microtubules that adhered tightly to the surface of cell
culture dish (see Figs. 2c, d), similar to the filopodia pro-
jections seen in melanoma and fibroblast cells [39]. Strik-
ingly, the formation of filopodia varied between the cell
types. About 80 % of T47D cells responded to drug by
forming filopodia on their edges, connecting to the bodies
of neighboring cells. In contrast, only a few control T47D
cells formed filopodia. By scanning electron microscopy
(SEM), we examined the surface architecture of the cells
treated with or without drug (Fig. 3a). Efavirenz-treated
T47D displayed numerous filopodial projections, as well as
infrequent large blebs on their cell surfaces and the sur-
faces had a very smooth texture. In contrast, control cells
exhibited shortened filopodia with a decrease in the number
of filopodia and the cell surface developed a wrinkled
texture. In the case of MCF7 cells, although the majority of
cells displayed filopodial structures, many efavirenz-trea-
ted cells also had elongated microtubule extensions, dif-
ferent from those of control MCF7 cells, in which short
microtubules concentrated around nucleating centers. To
further confirm the presence of the microtubule extensions,
cells were subjected to immunofluorescence staining with
anti-tubulin antibody, as a marker of the microtubule
cytoskeleton [32]. As shown in Fig. 3b, the drug-treated
MCF7 cells displayed elongated microtubules, with the
appearance of fusiform extensions protruding from the cell
periphery. In contrast, control cells contained few, if any,
microtubule extensions, suggesting that the microtubule
cytoskeletons were reorganised in response to drug. These
observations are consistent with earlier studies where
similar changes in microtubules were noticed in nevira-
pine-treated melanoma cells [18, 31]. Interestingly, T47D
cells did not show significant changes in microtubule
extensions either with, or without drug treatment. Fur-
thermore, Hs578T cells had no filopodia structures at all.
Instead, drug-treated cells become flattened compared to
untreated cells and exhibited a distinctive elongated and
reorganised clustering morphology, with a resumption of
contact inhibition (Fig. 2d and data not shown). Taken
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together, these observations suggest that efavirenz induces
morphological differentiation in a manner that is dependent
upon on the particular cell type.
RT inhibition reduces cell proliferation
To determine whether efavirenz had direct functional
effects on the rate of cell growth and proliferation, cells
were cultured with or without drug and cell proliferation
and viability assessed with XTT assays. We detected a
statistically significant decrease in the rate of cell prolif-
eration of drug-treated T47D, MCF7, and Hs578T cells
compared to parental cells or mock-treated controls
(Fig. 4a). Some cell type-specific differences were also
observed in the response to efavirenz. T47D cells had the
most pronounced response with a 60 % decrease in cell
proliferation, followed by 44 % in MCF7 cells. Hs578T
cells showed a weaker response to the drug, with a 33 %
reduction in the cell proliferation rate. To further confirm
the inhibitory effect of drug, cells were cultured with ef-
avirenz for 72 h, followed by growth in drug-free media for
48 h (Fig. 4b). The subsequent assays showed that, in the
absence of efavirenz, proliferation resumed to a rate almost
comparable to that of control cells, suggesting a reversible
effect of the drug on cell growth, consistent with previous
reports [18, 20]. To investigate whether the decrease in cell
proliferation was due to apoptosis of drug-treated cells,
cells were stained with a combination of 7-AAD (to detect
dead cells) and the proliferation marker Ki-67, and ana-
lysed by flow cytometry to identify cycling cells. No sig-
nificant differences in the induction of cell death were
observed in T47D, MCF7, and Hs578T cells with or
bFig. 3 RT inhibition leads to distinct changes in the surface
architecture of cells. a Scanning electron microscopy images
illustrates the formation of filopedial projections in DMSO-treated
control and RT-inhibited T47D cells. b Immunofluorescence of T47D
and MCF7 cells in the absence (control) or presence of RT inhibition
(efavirenz). Cells stained with anti-tubulin (green) and DAPI staining
of nucleus (blue) are shown. Bar represents 100 lM
Fig. 4 RT inhibition reduces
proliferation in breast cancer
cells. a 1 9 103 cells were
seeded in 96-well plates,
cultured with or without
efavirenz at the concentration of
15 lm for 72 h and color
formation measured at
absorbance 492 nm after 2, 6,
and 20 h incubation with XTT.
Analysis of parental cells was
performed in parallel. The
reference wavelength was
measured at the absorbance
690 nm. The staining intensity
represents the ratio of
absorbance at 492 and 690 nm.
Error bars indicate SD of three
independent assays. b An
equivalent number of cells were
cultured in the presence of
efavirenz for 72 h and the cells
then counted and replated in
drug-free medium for 48 h.
Proliferation in response to
drug-free medium was
measured using an ELISA
reader after staining with XTT.
The (*) and (**) symbols denote
a significant difference
compared to drug-treated cells,
with a p value \ 0.05 and
\0.001, respectively
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without drug treatment. At most, 17 % of cells were
recorded as having undergone apoptosis in both controls
and drug-treated cells (data not shown), suggesting that
drug had no specific effect on cell death or cytotoxicity.
Distinct gene expression signatures are associated
with RT inhibition
Having observed that efavirenz influenced cell growth and
morphological differentiation, we set out to investigate
differences in gene expression in drug-treated and
untreated cells. To accomplish this, we isolated total RNA
from DMSO-treated control and drug-treated T47D cells
and carried out gene expression analysis using Nimblegen
cDNA arrays (Build Hg18; 45,035 genes). We explored the
microarray results by carrying out gene ontology enrich-
ment analyses on the lists of 303 upregulated and 352
downregulated genes that were significantly different in
response to the drug treatment as determined by a student’s
t test (p values B 0.05 after correcting for multiple testing
using the Benjamini–Hochberg algorithm) and expression
fold changes C2 (upregulated) or B0.5 (downregulated).
The lists of differentially regulated genes were analysed
with the DAVID gene ontology web server (Database for
Annotation, Visualization, and Integrated Discovery). The
most significant gene clusters, with enrichment scor-
es C 1.3 (equivalent to a p value of 0.05 on the non-log
scale) are listed in Table 1. The heat map in Fig. 5a shows
a consistent pattern of change in the gene that were iden-
tified by the DAVID analysis and with false discovery rate
(FDR) \ 0.05 in the univariate analysis. The first-most
significant upregulated gene cluster contained genes
involved in cell projection and the formation of dendritic
spines (CDC42, FBX02, EXOC4, RSHL3, TTLL9, and
ATP1A2). The second-most significant cluster contained
genes involving the vacuolar membrane (ARL8A,
ATP6V1G2, SBF2, and STX8). Upregulation of cell pro-
jection genes that are essential for the biogenesis of cell
surfaces and genes in signaling pathways that control the
extension and maintenance of filopodia are likely to be
responsible for the differences in differentiation and
growth observed in these cells. Interestingly, the third most
significant gene cluster with a lower enrichment score of
1.17 contained many genes involved in cell junction for-
mation (PARD3, PDZD3, CX62, and UBN1) and synaptic
function (ENAH, ITSN1, and SYT17). PARD3 is a well-
known adaptor protein involved in asymmetrical cell
division and in the formation of epithelial tight junctions
through its interactions with other members of PARD
family of proteins [40]. To test the reliability of the
microarray gene expression fold changes, the expression of
some of the genes (CDC42, EXOC4, PARD3, and
PTP4A1) was confirmed by qRT-PCR, in additional cell
lines treated with or without RT inhibition (Fig. 5b). We
propose that the differences in gene expression in response
to efavirenz described above are likely to be factors in the
onset of cellular differentiation and morphological features
seen in the drug-treated cells.
In the DAVID analysis of the list of downregulated
genes, we found one statistically significant group
(Table 1). This cluster contained a number of downregu-
lated genes that are involved in the positive regulation of
cell migration and movement (CHRD, PTENP1, PTP4A1,
and TRIP6) and included a number of well-characterized
oncogenes, epidermal growth factor receptor (v-erb-b
Table 1 Gene ontology enrichment analysis of differentially
expressed genes using DAVID
Cluster Enrichment
score
Enriched term Counts PH Benjamini
Upregulated genes












Vacuole 8 256 4.5E1
Vacuole part 4 64 4.8E1
3 1.17 Cell junction 13 518 3.7E1



























The counts and population hits (PH) are the number of genes in the
gene list and background gene list, respectively, mapped to a specific
term. Benjamini: p value after correcting for false discovery rate
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erythroblastic leukemia viral homolog) (EGFR) and the
erythroblastic leukemia viral oncogene homolog (ERBB4).
The most notable findings were of the downregulation of
PRL tyrosine phosphatase, PTP4A1 (which stimulates cell
proliferation and invasive activity by downregulating p21
(Cip1/Waf1) protein [41]) and AAMP (which plays a role
Fig. 5 RT inhibition modulates
gene expression. a Heatmap of
log2 expression values of genes
in the four most significant gene
annotation clusters identified by
the DAVID analysis from lists
of genes that were 2-fold up- or
downregulated and with p value
for differential
expression B 0.05 after
Benjamini–Hochberg correction
for multiple testing. The color
scale corresponds to the degree
of fold change. Green
upregulated genes; red
downregulated genes, black no
change. b Confirmation of
differentially expressed genes
from the microarray expression
profiling experiments. Relative
levels of differentially
expressed genes were quantified
by qRT-PCR with primers
specific for their sequences. The
data are shown as the fold
change compared to mock-
treated cells after normalization
to the HPRT1 housekeeping
gene. Data are expressed as
mean ± SD (n = 4)
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in breast cancer cell migration [42]). qRT-PCR examina-
tion of the downregulation of PTP4A1 gene in additional
cell lines confirmed close correlation with gene expression
in the microarray experiment and the rate of proliferation
and differentiation seen in those cells (Fig. 5b). In addition
to the enriched annotation classes described above, the
KEGG (Kyoto Encyclopedia of Genes and Genomes)
pathways selected by DAVID as the most statistically
significant suggested that a number of the downregulated
genes, particularly tumor suppressor genes (PTENP1,
CASP9) might potentially be involved in the p53 signaling
pathway (data not shown). We also observed other less
significant enrichment clusters, but many of these clusters
contained only ankyrin repeat sequences whose biological
significance is not yet clearly understood. Interestingly,
several recent studies proposed that the activation of ret-
rotransposons might influence the cell transcriptome by
generating small regulatory RNAs or rewire transcriptional
networks by providing the transposon-derived transcription
factor binding sites (TBFs) for activation of many genes
[43, 44]. Although, at present, it is not known how might
L1 influence gene expression, our study demonstrates that
the inhibition of L1-encoded RT modulates the expression
of genes, many of which are involved in differentiation
pathways and cell growth, and thus further studies are
required in this direction. Nonetheless, the results pre-
sented here provide a direct functional link between the
expression of L1 elements and the development of breast
cancer. Looking at the induced genes that were specifically
expressed in response to the drug treatment, it is clear that
efavirenz triggers the expression of distinct set of genes
that can functionally modulate growth and differentiation
of cancer cells.
Discussion
The contribution of L1 retrotransposons to pathological
processes other than those due to genomic insertions is
poorly understood. The expression of L1 protein is signifi-
cantly elevated in the most types of breast cancer cells [13,
24, 25], but the functional significance of this expression on
gene regulation is unknown. In addition, it is unclear
whether L1 expression is an active process that drives
cancer growth or a secondary bystander of cancer trans-
formation. Studies carried out in melanoma and prostate
cancer cell lines have shown that efavirenz selectively
inhibits endogenous RT activity without interfering with the
telomerase-associated RT (TERT) enzyme [19, 31]. The
inhibition of L1-encoded RT has been associated with
reduced growth in cancer cells and in nude mice [8, 9, 18].
However, little is known about the molecular events that
govern such cell growth and differentiation.
In the present study, we investigated the endogenous
expression of the L1-encoded RT enzyme in a range of
breast cancer cell lines and evaluated whether inhibition of
RT induces morphological changes in these cells in a way
that can be directly attributed to changes in gene expres-
sion. While there appears to be some differences in the
level of RT expression, similar to the changes in the
expression of L1 ORF2 protein seen in our recent study
[13, 25], we observed that cell type-specific morphological
differences in response to RT inhibition by efavirenz.
T47D cells underwent the most marked changes in mor-
phological differentiation with the appearance of filopodial
projections protruding from the cell periphery, whereas
MCF7 exhibited elongated microtubule extensions that
adhered tightly to their substrate, similar to the phenotypic
changes seen in melanoma A-375 and prostate cancer cell
lines [18, 20]. Hs578T cells had a weak response to the
drug. Concomitant with this, we also noticed reduced cell
growth and proliferation which was largely independent of
cell death or cytotoxicity. These observations suggest a
causative role for L1-encoded RT in cancer growth. This is
further supported by the finding that small interference
RNAi against the L1-encoding RT enzyme induces mor-
phological and proliferative changes that are almost iden-
tical to those caused by efavirenz and other NNRT1 drugs
[18, 20]. Notably, however, downregulation of the HERV-
encoded RT enzyme has no significant effects on cell
proliferation and differentiation [19], suggesting that L1-
encoded RT plays specific roles in pathological processes.
Given that efavirenz attenuates the tumorigenic pheno-
type of breast cancer cell lines, it is of obvious interest to
determine the biological pathways affected by RT inhibi-
tion. Although it was previously shown that RT inhibition
changes the expression of few cell cycle-related genes [18],
a direct connection between the phenotypic changes
induced by efavirenz and changes in gene expression has
been largely missing. In this study we analyzed the global
changes in gene expression that occur during RT inhibition.
Using gene expression profiling with microarrays and GO
enrichment analysis, our study identified three clusters of
induced genes. The first upregulated cluster contained
genes involved in cell projection and dendritic spine for-
mation. This cluster included EXOC4 which is essential for
the biogenesis of epithelial cell surfaces through its inter-
actions with the actin cytoskeletal remodeling and vesicle
transport machinery [45]. The cluster also contained
CDC42 which regulates the signaling pathways that control
the extension and maintenance of filopodia [33]. The sec-
ond cluster contained genes involved in the cell cycle and
genes associated with the centrosome and mitotic spindle
formation. The third cluster contained genes involved in
cell-to-cell junction formation (PARD3, PDZD3, CX62,
and UBN1) and synaptic function (ENAH, ITSN1, and
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SYT17). PARD3 is a member of a family of adaptor pro-
teins playing a central role in the formation of epithelial
tight junctions by interacting with other members of the
PARD family of proteins [40]. Furthermore, the present
study also identified a number of downregulated genes with
roles in cell proliferation, cell migration and invasive
activity, and that promote metastasis. Downregulation of
PTP4A1 and AAMP are notable, and the expression of
these genes is required for conferring transformed pheno-
types in human cancers [41, 42], implicating their roles in
the tumorigenesis. Strikingly, our study has identified that
the downregulation of PTP4A1 is common in all RT-
inhibited breast cancer cells. In summary, our study dem-
onstrates that RT inhibition altered the expression of a
number of key genes, which are functionally associated
with cell projections, cell cycle progression, and cell-to-
cell junctions. It appears possible that altered expression of
these genes alone could be sufficient to revert undifferen-
tiated cells to more differentiated phenotypes.
At this stage, the underlying mechanism of the activation
or repression of gene expression that occurs during inhibition
of RT is unclear. One possibility is that inhibition of RT
substantially reduces the activity of L1 retrotransposition,
which in turn reduces the restructuring of the genome and
transcriptome that occurs during L1 retrotransposition [46].
One could therefore, argue that the changes in gene expres-
sion that follow RT inhibition and that were identified by our
microarray analysis are likely to contribute to phenotypic
changes. Another possibility is that L1-encoded RT may
have a direct role in the transcriptional activation or repres-
sion of some of these genes. Recently, it has been postulated
that the retrotransposition activity of L1 elements might
interfere with the transcription machinery of cells and
thereby be involved in the development and progression of
cancer [47]. A computational study proposes that the
expression of L1 elements may regulate the network of genes
by contributing a source of transcriptional regulatory signals
previously not present in the promoters of genes [48].
Remarkably, a recent study sequencing the 50-most nucleo-
tides of RNAs from normal, and neoplastic tissues identified
that highly specific patterns of transcriptional activity occur
due to the expression of L1 elements [49]. In addition, sev-
eral other studies have reported that L1 elements in human
cancer are capable of interfering with normal gene expres-
sion by providing alternative promoters for expression of
nearby oncogenes [50] or by disrupting the expression of
tumor suppressor genes by epigenetic dysregulation of L1
sequences [51]. Thus, it is possible that one or more of these
mechanisms might contribute to the reduction in cell growth
following inhibition of L1-encoded RT activity in breast
cancer cells. Given that the observed phenotypic changes
were reversible when RT inhibition was stopped, it is pos-
sible that RT inhibition may act through reversible
epigenetic changes that alter the expression of genes. Con-
sistent with this, there is growing evidence from studies with
a number of drugs, which are currently in clinical trials [52],
that epigenetic changes can bypass the genetic alterations
caused by malignancy and reprogram gene expression by
changing the epigenetic state of the cells. Thus, identifying
the epigenetic mechanisms by which RT inhibition affects
genome-wide gene expression may help us to understand the
crosstalk between RT and the pathogenesis of breast cancer.
Conclusion
This study has explored the relationship between the
expression of endogenous L1-encoded RT and the patho-
logical features of breast cancer cells. In this study we have
shown, first, that RT activity is widespread in breast cancer
cells. Second, abnormal cell growth and the undifferenti-
ated state of breast cancer cells are closely associated with
RT activity. Inhibition of RT reduces cell proliferation
(which is not related to cell death or cytotoxicity) and
induces morphological differentiation of cancer cells.
Third, RT inhibition modulates the expression of a distinct
set of genes that are functionally associated with cell
growth and differentiation. This study is the first to profile
the changes in gene expression that occur during cell dif-
ferentiation in relation to inhibition of L1-encoded RT by
antiviral drugs. We found that considerable cell type-spe-
cific morphological differences exist in response to RT
inhibition that may be related to the biological and path-
ological features of breast cancer cells. The association
found between RT inhibition and the observed changes in
gene expression suggest that further studies of the network
of genes are warranted in breast cancer cells.
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